<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730912</url>
  </required_header>
  <id_info>
    <org_study_id>P05539</org_study_id>
    <nct_id>NCT00730912</nct_id>
  </id_info>
  <brief_title>Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)</brief_title>
  <official_title>Protocol for Post-approval Commitment Study of Loratadine for PPK Analysis in Japanese Pediatric and Adults Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post marketing study to confirm the appropriate dose of loratadine in children by
      obtaining drug concentration data at multiple time points per child and adult patient, after
      the patient receives repeated administrations of the approved dose of loratadine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Maximum Plasma Concentration (Cmax) of SCH 29851 (Unchanged Drug; Loratadine), SCH 34117 (Active Metabolite), and SCH 45581 (3OH-SCH 34117)</measure>
    <time_frame>After 2 and 4 weeks of treatment, and after 1 and 3 weeks of treatment if participant agreed</time_frame>
    <description>SCH 29851: Two-compartment model used as basic pharmacokinetic (PK) model. Individual Cmax estimated with basic PPK parameters (apparent total body clearance (CL/F), apparent distribution volumes of central compartment (Vc/F) and peripheral compartment (Vp/F), apparent inter-compartmental clearance (Q/F), absorption rate constant (Ka), lag time, inter- and intra-individual variation) by Bayesian method. SCH 34117/SCH 45581: One-compartment model used as basic PK model. Individual Cmax was estimated with PPK parameters (above) on final model by Bayesian method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Area Under the Plasma Concentration Time Curve (AUC) of SCH 29851 (Unchanged Drug), SCH 34117 (Active Metabolite), and SCH 45581 (3OH-SCH 34117)</measure>
    <time_frame>After 2 and 4 weeks of treatment, and after 1 and 3 weeks of treatment if participant agreed</time_frame>
    <description>SCH 29851: Two-compartment model used as basic pharmacokinetic (PK) model. Individual AUC estimated with basic PPK parameters (apparent total body clearance (CL/F), apparent distribution volumes of central compartment (Vc/F) and peripheral compartment (Vp/F), apparent inter-compartmental clearance (Q/F), absorption rate constant (Ka), lag time, inter- and intra-individual variation) by Bayesian method. SCH 34117/SCH 45581: One-compartment model used as basic PK model. Individual AUC was estimated with PPK parameters (above) on final model by Bayesian method.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">261</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Pediatrics 3 to 6 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatrics 3 to 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pediatrics 7 to 15 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatrics 7 to 15 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults 16 to 64 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults 16 to 64 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loratadine</intervention_name>
    <description>Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks</description>
    <arm_group_label>Pediatrics 3 to 6 years</arm_group_label>
    <other_name>Claritin</other_name>
    <other_name>SCH 29851</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loratadine</intervention_name>
    <description>loratadine 10 mg tablet once daily for 4 weeks</description>
    <arm_group_label>Pediatrics 7 to 15 years</arm_group_label>
    <other_name>Claritin</other_name>
    <other_name>SCH 29851</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loratadine</intervention_name>
    <description>loratadine 10 mg tablet once daily for 4 weeks</description>
    <arm_group_label>Adults 16 to 64 years</arm_group_label>
    <other_name>Claritin</other_name>
    <other_name>SCH 29851</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with perennial allergic rhinitis who satisfy all of the following criteria were
        enrolled in the study:

          -  Pediatric patients between the ages of 3 and 15 years and adult patients between the
             ages of 16 and 64 at the time of providing informed consent.

          -  Outpatients of either sex.

          -  Pediatric patients for whom written informed consent can be obtained from the guardian
             before the start of the study. Adult patients from whom written informed consent can
             be obtained (for patients between the ages of 16 and 19, the guardian must also
             provide written informed consent).

          -  Pediatric patients who have the ability to make entries in the patient diary (Record
             of Drugs and Nasal Symptoms) or entry in the diary is made possible by the guardian.
             Adult patients who have the ability to make entries in the patient diary.

          -  Patients for whom treatment with loratadine monotherapy is judged appropriate based on
             symptoms of allergic rhinitis during the pretreatment observation period.

          -  Patients confirmed to be allergic to perennial allergen

        Exclusion Criteria:

          -  Patients with a history of epileptic seizures or organic brain disorder in whom there
             is a possibility that epileptic seizures may be induced

          -  Patients with a history of hypersensitivity to any component of this drug

          -  Patients who are pregnant or who may be pregnant, and nursing women

          -  Patients with severe hepatic, renal, cardiac, or hematological disease or other
             serious complications and whose general condition is poor

          -  Patients participating in another clinical study or who have been in a clinical study
             within the last 30 days.

          -  Other patients judged inappropriate for study by the investigator or sub-investigator

          -  Patients allergic to pollen (cedar, mugwort, common ragweed, orchard grass, etc.) and
             the pollen season is during the period from 7 days before registration to the end of
             study drug administration

          -  Patients who developed diseases which might affect nasal symptoms (acute upper
             respiratory tract infection, acute pharyngo-laryngitis, or acute tonsillitis) in the 7
             days before registration

          -  Patients who received treatment for allergic rhinitis in the 7 days before
             registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <results_first_submitted>June 3, 2010</results_first_submitted>
  <results_first_submitted_qc>June 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 5, 2010</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pediatrics 3 to 6 Years</title>
          <description>Pediatrics 3 to 6 years of age received loratadine 5 mg/day for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Pediatrics 7 to 15 Years</title>
          <description>Pediatrics 7 to 15 years of age received loratadine 10 mg/day for 28 days</description>
        </group>
        <group group_id="P3">
          <title>Adults 16 to 64 Years</title>
          <description>Adults 16 to 64 years of age received loratadine 10 mg/day for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pediatrics 3 to 6 Years</title>
          <description>Pediatrics 3 to 6 years of age received loratadine 5 mg/day for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Pediatrics 7 to 15 Years</title>
          <description>Pediatrics 7 to 15 years of age received loratadine 10 mg/day for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Adults 16 to 64 Years</title>
          <description>Adults 16 to 64 years of age received loratadine 10 mg/day for 28 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="261"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 3-6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 7 and 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 16 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Maximum Plasma Concentration (Cmax) of SCH 29851 (Unchanged Drug; Loratadine), SCH 34117 (Active Metabolite), and SCH 45581 (3OH-SCH 34117)</title>
        <description>SCH 29851: Two-compartment model used as basic pharmacokinetic (PK) model. Individual Cmax estimated with basic PPK parameters (apparent total body clearance (CL/F), apparent distribution volumes of central compartment (Vc/F) and peripheral compartment (Vp/F), apparent inter-compartmental clearance (Q/F), absorption rate constant (Ka), lag time, inter- and intra-individual variation) by Bayesian method. SCH 34117/SCH 45581: One-compartment model used as basic PK model. Individual Cmax was estimated with PPK parameters (above) on final model by Bayesian method.</description>
        <time_frame>After 2 and 4 weeks of treatment, and after 1 and 3 weeks of treatment if participant agreed</time_frame>
        <population>Number of participants for SCH 29851 were 53, 104, and 104. Number of participants for SCH 34117 were 53, 102, and 104. Number of participants for SCH 44581 were 53, 99, and 104.</population>
        <group_list>
          <group group_id="O1">
            <title>Pediatrics 3 to 6 Years</title>
            <description>Pediatrics 3 to 6 years of age received loratadine 5 mg/day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Pediatrics 7 to 15 Years</title>
            <description>Pediatrics 7 to 15 years of age received loratadine 10 mg/day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Adults 16 to 64 Years</title>
            <description>Adults 16 to 64 years of age received loratadine 10 mg/day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Plasma Concentration (Cmax) of SCH 29851 (Unchanged Drug; Loratadine), SCH 34117 (Active Metabolite), and SCH 45581 (3OH-SCH 34117)</title>
          <description>SCH 29851: Two-compartment model used as basic pharmacokinetic (PK) model. Individual Cmax estimated with basic PPK parameters (apparent total body clearance (CL/F), apparent distribution volumes of central compartment (Vc/F) and peripheral compartment (Vp/F), apparent inter-compartmental clearance (Q/F), absorption rate constant (Ka), lag time, inter- and intra-individual variation) by Bayesian method. SCH 34117/SCH 45581: One-compartment model used as basic PK model. Individual Cmax was estimated with PPK parameters (above) on final model by Bayesian method.</description>
          <population>Number of participants for SCH 29851 were 53, 104, and 104. Number of participants for SCH 34117 were 53, 102, and 104. Number of participants for SCH 44581 were 53, 99, and 104.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCH 29851</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="1.78"/>
                    <measurement group_id="O2" value="5.54" spread="3.15"/>
                    <measurement group_id="O3" value="6.48" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCH 34117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="1.26"/>
                    <measurement group_id="O2" value="4.30" spread="1.63"/>
                    <measurement group_id="O3" value="4.61" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCH 45581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="0.76"/>
                    <measurement group_id="O2" value="2.56" spread="0.86"/>
                    <measurement group_id="O3" value="2.35" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Plasma Concentration Time Curve (AUC) of SCH 29851 (Unchanged Drug), SCH 34117 (Active Metabolite), and SCH 45581 (3OH-SCH 34117)</title>
        <description>SCH 29851: Two-compartment model used as basic pharmacokinetic (PK) model. Individual AUC estimated with basic PPK parameters (apparent total body clearance (CL/F), apparent distribution volumes of central compartment (Vc/F) and peripheral compartment (Vp/F), apparent inter-compartmental clearance (Q/F), absorption rate constant (Ka), lag time, inter- and intra-individual variation) by Bayesian method. SCH 34117/SCH 45581: One-compartment model used as basic PK model. Individual AUC was estimated with PPK parameters (above) on final model by Bayesian method.</description>
        <time_frame>After 2 and 4 weeks of treatment, and after 1 and 3 weeks of treatment if participant agreed</time_frame>
        <population>Number of participants for SCH 29851 were 53, 104, and 104. Number of participants for SCH 34117 were 53, 102, and 104. Number of participants for SCH 44581 were 53, 99, and 104.</population>
        <group_list>
          <group group_id="O1">
            <title>Pediatrics 3 to 6 Years</title>
            <description>Pediatrics 3 to 6 years of age received loratadine 5 mg/day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Pediatrics 7 to 15 Years</title>
            <description>Pediatrics 7 to 15 years of age received loratadine 10 mg/day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Adults 16 to 64 Years</title>
            <description>Adults 16 to 64 years of age received loratadine 10 mg/day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Plasma Concentration Time Curve (AUC) of SCH 29851 (Unchanged Drug), SCH 34117 (Active Metabolite), and SCH 45581 (3OH-SCH 34117)</title>
          <description>SCH 29851: Two-compartment model used as basic pharmacokinetic (PK) model. Individual AUC estimated with basic PPK parameters (apparent total body clearance (CL/F), apparent distribution volumes of central compartment (Vc/F) and peripheral compartment (Vp/F), apparent inter-compartmental clearance (Q/F), absorption rate constant (Ka), lag time, inter- and intra-individual variation) by Bayesian method. SCH 34117/SCH 45581: One-compartment model used as basic PK model. Individual AUC was estimated with PPK parameters (above) on final model by Bayesian method.</description>
          <population>Number of participants for SCH 29851 were 53, 104, and 104. Number of participants for SCH 34117 were 53, 102, and 104. Number of participants for SCH 44581 were 53, 99, and 104.</population>
          <units>ngâ€¢hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCH 29851</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.77" spread="14.87"/>
                    <measurement group_id="O2" value="26.13" spread="22.22"/>
                    <measurement group_id="O3" value="34.68" spread="37.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCH 34117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.33" spread="15.63"/>
                    <measurement group_id="O2" value="59.52" spread="23.73"/>
                    <measurement group_id="O3" value="68.01" spread="23.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCH 45581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.54" spread="11.43"/>
                    <measurement group_id="O2" value="42.28" spread="14.40"/>
                    <measurement group_id="O3" value="40.75" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pediatrics 3 to 6 Years</title>
          <description>Pediatrics 3 to 6 years of age received loratadine 5 mg/day for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Pediatrics 7 to 15 Years</title>
          <description>Pediatrics 7 to 15 years of age received loratadine 10 mg/day for 28 days</description>
        </group>
        <group group_id="E3">
          <title>Adults 16 to 64 Years</title>
          <description>Adults 16 to 64 years of age received loratadine 10 mg/day for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator (sub-investigator) will disclose the results and knowledge obtained through this study after discussion with the Sponsor and approval is obtained from the Sponsor.
If the investigator (sub-investigator) is to present the results obtained from this study at a medical conference or medical journal, approval of the Sponsor must be obtained beforehand</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

